Ultima Genomics wins sequencing role in Singapore's 450,000-person precision medicine program
Founder Gilad Almogy's UG200 joins Lucence and QIAGEN for SG-INSIGHT, as Singapore expands genome sequencing from healthy volunteers to patients in public hospitals.
By RuntimeWire Staff · Published
Primary source: PR Newswire Business Technology
Why it matters
Singapore is testing whether whole genomes can move from research cohorts into routine public healthcare for about 450,000 people. Ultima's selection gives a well-funded sequencing challenger a role in a national clinical program alongside Illumina.
Gilad Almogy has spent a decade arguing that genome sequencing gets useful when it gets cheap enough to run on patients at population scale. On November 2nd, 2026, his company got its biggest clinical test yet: Ultima Genomics said its UG200 platform was selected for SG-INSIGHT, a cohort under Phase III of Singapore's National Precision Medicine program.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.